RITUXIMAB IN SUBJECTS WITH ISN/RPS CLASS III OR IV LUPUS NEPHRITIS

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可在其他CRISP条目中表示。所列机构为 中心，但不一定是研究者所在的机构。 本研究的目的是探讨利妥昔单抗联合吗替麦考酚酯（MMF）与安慰剂联合MMF治疗狼疮性肾炎的安全性和有效性。 利妥昔单抗是一种单克隆抗体，它是一种蛋白质，有助于保护身体免受外来物质的侵害。 它减少了体内某些类型的B细胞，这可能在炎症中很重要。 利妥昔单抗已用于少数狼疮肾炎患者，本研究旨在进一步评估利妥昔单抗是否会减少狼疮和狼疮肾炎的体征和症状。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to investigate the safety and efficacy of rituximab in combination with mycophenolate mofetil (MMF) compared with placebo in combination with MMF in the treatment of lupus nephritis. Rituximab is a monoclonal antibody, which is a protein that helps protect the body against foreign materials. It decreases some types of B-cells in the body which may be important in inflammation. Rituximab has been used in a small number of patients with lupus nephritis, and this study is designed to further evaluate whether rituximab would reduce the signs and symptoms of lupus and lupus nephritis.